Pluristem Therapeutics Inc

NASDAQ:PSTI  
3.63
+0.09 (+2.54%)
Other Pre-Announcement

Pluristem Expects To Announce Interim Analysis Results For Global Pivotal Phase III Study Of PLX-PAD In CLI In Q4 Calendar 2020

Published: 09/15/2020 13:39 GMT
Pluristem Therapeutics Inc (PSTI) - Pluristem Therapeutics - in Q4 Calendar 2020, Expect to Announce Interim Analysis Results for Global Pivotal Phase Iii Study of Plx-pad in Cli.
Pluristem Therapeutics - Over Past Few Weeks, Shifted Clinical Site Openings From New York Area to Other Regions in U.S. for Phase Ii Covid-19 Study.
Pluristem Therapeutics - Also Considering Adding Clinical Partners to Accelerate Site Openings for Phase Ii Covid-19 Study.
Pluristem Therapeutics - Updating Expectation of Completing Enrollment of Phase Ii Covid-19 Study in Q1 of Calendar Year 2021.